Investors have backed Oxford University spin-off ONI Ltd. with $75 million to push commercialization of its nanoimaging technology. The startup’s flagship product Nanoimager is a desktop, super resolution microscope capable of visualizing, tracking, and imaging individual molecules in living cells with 20 nm resolution. The technology is already in use with biomedical companies to aid development of more efficient, targeted therapies.

Cancer therapy developer Immpact Bio USA Inc. has raised $111 million to further its "logic gate"-based CAR T-cell platform, the source of a CD19/CD20 bispecific in phase I testing for B-cell non-Hodgkin lymphoma patients whose disease has returned or who has stopped responding to treatment. New data from that study, showing complete remissions in seven of eight patients treated, accompanied the appointment of a new president and CEO for the company as well as a new board chair.

Mabwell Bioscience Co. Ltd. raised ¥3.48 billion ($547.9 million) in a Shanghai STAR Market IPO on Jan. 18 to support company R&D efforts and plans to build an antibody production plant. Though oversubscribed, the offering got a cool market reception, with shares plunging nearly 30% from a ¥32 open (US$27.96), then closing at ¥24.50 on the first day of trading before recovering slightly to ¥27.40 on Jan. 20.

While med-tech financings in 2021 fell about 17% below the amount raised in 2020, the industry still collected $49.26 billion, significantly more than each of the two previous years, and driven primarily by digital health and diagnostic technologies.

LONDON – Engitix Therapeutics Ltd. has raised $54 million in a series A round to advance early programs arising from its human extracellular matrix (ECM) target discovery platform towards the clinic with the support of new partner and equity investor Dompé Farmaceutici SpA.